Contract notice: supply of exclusive medicines: alectinib, pirfenidone, obinutuzumab, dornase alfa
, rituximab, atezolizumab, trastuzumab, trastuzumab emtansin
Currently, the company expects several biosimilars to be in clinical trials: Rituximab biosimilar (JHL1101) to treat rheumatoid arthritis and Non-Hodgkin's Lymphoma; Dornase alfa
biosimilar (JHL1922) to manage symptoms of cystic fibrosis; as well as Trastuzumab biosimilar (JHL1188) to treat breast cancer.
NORDIC BUSINESS REPORT-December 21, 2017-JHL submits clinical trial application with the Dutch Healthcare Authority for proposed clinical trial of Dornase Alfa
Biosimilar in the Netherlands
In contrast to control groups patients from the main group received the inhalation with surfactant emulsion 12 ml per kg, dornase alfa
(25 mg, 2 times a day), almitrin (scheme).
He was on chronic antimicrobial therapy (inhaled colistin and oral azithromycin), as well as inhaled salbutamol, inhaled corticosteroids, dornase alfa
, pancreatic enzymes, domperidone, omeprazole, PEG 3350, multivitamins including Vitamins D and K, insulin, ursodeoxycolic acid, furosemide and amilioride.
Acetylcysteine (Mucomyst) and guaifenesin are also helpful, but dornase alfa
(Pulmozyme) is not indicated in non-CF patients and was actually harmful in one study.
A two-year randomized, placebo-controlled trial of dornase alfa
In young patients with cystic fibrosis with mild lung function abnormalities.
The purpose of this article is to give a brief overview of how the drug dornase alfa
(Pulmozyme (R), Genentech) affects CF, as well as how it is administered, its side effects and case studies.
A Crossover, Randomized, Controlled Trial of Dornase Alfa
Before Versus After Physiotherapy in Cystic Fibrosis.
(Pulmozyme) treatment reduced exacerbations in healthy cystic fibrosis patients who were 6-10 years old.
Pulmozyme(R) (dornase alfa
) Inhalation Solution sales decreased 13 percent to $28.1 million in the second quarter of 2001 compared to $32.3 million in the second quarter of 2000.
Possibly the most innovative drug to win FDA approval last year was Genentech Inc.'s dornase alfa
, which was what Hussar described as the first major advance for cystic fibrosis patients in 30 years.